Hybrid-Core Tech Speeds Next-Generation Genomic Sequencing Analysis Pipeline
|
By LabMedica International staff writers Posted on 05 Mar 2013 |
A new hybrid-core system increases genomic application performance with lower ownership costs.
Convey Computer (Richardson, TX, USA) announced that the Broad Institute (Cambridge, MA, USA) has installed a Convey HC-2 system as part of their high performance compute farm. The Broad Institute) plans to use the system to speed their genomic pipelines and slash their overall cost of analysis. The Broad Institute is one of the leading biomedical and genomic research centers, generating terabases of sequence data per day.
Convey is working closely with the Broad as they incorporate the Convey system into their pipeline. “We are pleased that the Broad has selected Convey to accelerate critical portions of their next-generation sequencing analysis pipeline,” explained Dr. George Vacek, Director of Convey Computer’s Life Sciences business unit. “Broad is a leader in the adoption of new sequencing technology and in development of corresponding analysis methods. Our ongoing relationship to optimize their analysis tools will have a high impact on researchers worldwide.”
The Broad Institute purchased the Convey system to explore how the hybrid-core computer could accelerate their pipelines while reducing costs. “Although BWA is not a large part of the overall pipeline wall time, in terms of CPU dollars spent it is a very large component,” explained Tim Fennell, director of informatics for the Broad’s genomics platform. “With the Convey system, we expect to increase performance of BWA 10-fold. The Convey system will allow us to increase our efficiency and complete more analysis per dollar.” (The Burrows-Wheeler Aligner [BWA] is an efficient program that aligns comparatively short nucleotide sequences against a long reference sequence such as the human genome.)
Installation of the Convey system at the Broad was quick and easy. “Installing the Convey system was just like installing any other piece of compute hardware. It required no customization at all, fitting naturally into our existing infrastructure,” said Eric Jones, manager of research computing. “Additionally, I’m impressed with Convey’s customer support; I can quickly and easily talk to knowledgeable people.”
Convey’s hybrid-core architecture pairs classic Intel x86 microprocessors with a coprocessor comprised of FPGAs. Particular algorithms—BWA-based alignment, for example—are optimized and translated into code that is loadable onto the coprocessor at runtime. The systems help customers dramatically increase performance over industry standard servers while reducing energy costs associated with high-performance computing.
The world’s first hybrid-core computer, the Convey Computer’s system, combines the low cost and simple programming model of a commodity system with the performance of personalized hardware architecture. Using the Convey hybrid-core systems, users worldwide in industries such as life sciences, research, sophisticated analytics, and the government/defense are appreciating increased application performance and lower costs of ownership.
Related Links:
Convey Computer
Broad Institute
Convey Computer (Richardson, TX, USA) announced that the Broad Institute (Cambridge, MA, USA) has installed a Convey HC-2 system as part of their high performance compute farm. The Broad Institute) plans to use the system to speed their genomic pipelines and slash their overall cost of analysis. The Broad Institute is one of the leading biomedical and genomic research centers, generating terabases of sequence data per day.
Convey is working closely with the Broad as they incorporate the Convey system into their pipeline. “We are pleased that the Broad has selected Convey to accelerate critical portions of their next-generation sequencing analysis pipeline,” explained Dr. George Vacek, Director of Convey Computer’s Life Sciences business unit. “Broad is a leader in the adoption of new sequencing technology and in development of corresponding analysis methods. Our ongoing relationship to optimize their analysis tools will have a high impact on researchers worldwide.”
The Broad Institute purchased the Convey system to explore how the hybrid-core computer could accelerate their pipelines while reducing costs. “Although BWA is not a large part of the overall pipeline wall time, in terms of CPU dollars spent it is a very large component,” explained Tim Fennell, director of informatics for the Broad’s genomics platform. “With the Convey system, we expect to increase performance of BWA 10-fold. The Convey system will allow us to increase our efficiency and complete more analysis per dollar.” (The Burrows-Wheeler Aligner [BWA] is an efficient program that aligns comparatively short nucleotide sequences against a long reference sequence such as the human genome.)
Installation of the Convey system at the Broad was quick and easy. “Installing the Convey system was just like installing any other piece of compute hardware. It required no customization at all, fitting naturally into our existing infrastructure,” said Eric Jones, manager of research computing. “Additionally, I’m impressed with Convey’s customer support; I can quickly and easily talk to knowledgeable people.”
Convey’s hybrid-core architecture pairs classic Intel x86 microprocessors with a coprocessor comprised of FPGAs. Particular algorithms—BWA-based alignment, for example—are optimized and translated into code that is loadable onto the coprocessor at runtime. The systems help customers dramatically increase performance over industry standard servers while reducing energy costs associated with high-performance computing.
The world’s first hybrid-core computer, the Convey Computer’s system, combines the low cost and simple programming model of a commodity system with the performance of personalized hardware architecture. Using the Convey hybrid-core systems, users worldwide in industries such as life sciences, research, sophisticated analytics, and the government/defense are appreciating increased application performance and lower costs of ownership.
Related Links:
Convey Computer
Broad Institute
Latest BioResearch News
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
Channels
Clinical Chemistry
view channelMultiprotein Plasma Panel Identifies Remission in Vasculitis
Vasculitis causes immune-mediated inflammation of blood vessel walls and can lead to kidney and lung damage. Clinicians rely on immunosuppressive drugs, but treatment carries significant side effects and... Read more
Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
Kidney transplantation remains constrained by organ scarcity and uncertainty about the quality of deceased-donor kidneys. In the United States, more than 92,000 people are awaiting a kidney transplant,... Read moreMolecular Diagnostics
view channel
New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients
Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more
Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency
Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Gut “Memory” May Explain Why IBD Flares Return
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by recurring flare-ups that damage the intestinal mucosa and remain difficult to predict.... Read more
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read moreMicrobiology
view channel
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read morePathology
view channel
AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channelTumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring
NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more







